Categorized | Expert Insights, QbD News

Published Pharma R&D Costs are Highly Exaggerated, According to a London School of Economics Journal Article

    Published Pharma R&D Costs are Highly Exaggerated, According to a London School of Economics Journal Article

    By Agnes Shanley

    Have pharmaceutical R&D costs, the Tufts University numbers always bandied about, been vastly exaggerated? So asks a paper (download the PDF here) recently published by Stanford, Princeton and University of Victoria (British Columbia) professors,  in the London School of Economics and Political Science’s journal, BioSocieties.

    The authors examine and critique all the bases for current estimates, and suggest that they have been inflated for lobbying and other reasons, ending the article with the following statement, which some might find hard to argue with.  ”Current incentives reward companies to develop mainly new medicines of little advantage and compete for market share at high price, rather than develop superior medicines with public funding at low cost…”

    Related posts:

    1. School Support: How Universities Can Aid Your QbD Efforts
      Where will your early-phase QbD money be better spent—with your employees, or sleuthing and solving with graduate students and post-docs?...
    2. You’re the CEO: Can You Justify the Costs of These QbD Projects?
      Here are two sample case studies where QbD could be applied to blockbuster drugs. Can you provide financial justification for...
    3. Ali Afnan: Yes, Virginia, There is a Santa Claus (But Little Science, or Change, in Pharma…Yet)
      In the end, this industry is what we make it. Let’s base our actions on science and our goals, on...
    4. Making Change: Five Steps for Pharma
      Successful change doesn't come easy, says Emerson Process Management's Melissa Herkt. Her case for change involves five key steps: vision,...
    5. Pharma Wastes Over $60 Billion on R&D Each Year: Outgoing EMA Chief, Thomas Lonngren
      Pharmaceutical Quality by Design received an unofficial boost in comments made by the outgoing chief of the European Medicines Agency,...

    One Response to “Published Pharma R&D Costs are Highly Exaggerated, According to a London School of Economics Journal Article”

    1. jochen.koenig says:

      Please note that, as least as much as with the Tufts’ estimates, this article should be read with a critical mind. There has been intense discussion about some of its weaknesses in the community. Some of the arguments can be found at http://pipeline.corante.com/archives/2011/03/07/the_costs_of_drug_research_beginning_a_rebuttal.php and subsequent blog entries.

    Trackbacks/Pingbacks


    Leave a Reply

    You must be logged in to post a comment.